Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| HEAL Initiative: JCOIN Phase II Innovation Hubs (R01 Clinical Trial Optional) | RFA-DA-25-062 | NIDA | Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if… More | ||
| HEAL Initiative: JCOIN Phase II Clinical Research Hubs (UM1 Clinical Trial Required) | RFA-DA-25-025 | NIDA | Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if… More | ||
| HEAL Initiative: JCOIN Phase II Economic Research Resource Center (U24 Clinical Trial Optional) | RFA-DA-25-061 | NIDA | Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if… More | ||
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) | RFA-DA-24-038 | NIDA | This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards… More | ||
| Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) | RFA-DA-26-019 | NIDA | Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples.… More | ||
| Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional) | RFA-DA-26-018 | NIDA | Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples.… More | ||
| Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Clinical Trials Optional) | RFA-DA-26-017 | NIDA | This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical… More | ||
| Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Clinical Trials Optional) | RFA-DA-26-016 | NIDA | This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical… More | ||
| Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R33 Clinical Trial Optional) | RFA-DA-26-024 | NIDA | Outside of research with adolescents, there is a relative dearth of research on how to effectively leverage and support relationships between people with addiction and their loved ones to improve… More | ||
| Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed) | RFA-DA-26-008 | NIDA | The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this… More |